Conditional recurrence-free survival after curative esophagectomy: individual patient data analysis of 11 trials

Multiple Myeloma (MM)

Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis

Blood Cancer J

Souto Filho JTD, Cantadori LO, Crusoe EQ, Hungria V, Maiolino A

doi: 10.1038/s41408-025-01413-7

Lung, Respiratory and Thoracic Cancer

Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis

Lancet Oncol

Di Federico A, Stumpo S, Mantuano F, De Giglio A, Lo Bianco F, Pecci F, Alessi JV, Wang X, Sperandi F, Melotti B, Gelsomino F, Skoulidis F, Garassino MC, Peters S, Awad MM, Ardizzoni A, Ricciuti B

doi: 10.1016/S1470-2045(25)00429-2

Breast Cancer

Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials

Lancet Oncol

Conforti F, Holtschmidt J, Nekljudova V, Sala I, Pagan E, Solbach C, Untch M, Denkert C, Bagnardi V, Pala L, Fasching PA, Schneeweiss A, Lück HJ, Viale G, De Pas T, van Mackelenbergh M, Huober J, Müller V, Link T, Karn T, Reinisch M, Marmé F, Bjelic-Radisic V, Schem C, Hartkopf A, Stickeler E, Hanusch C, Blohmer JU, Fehm T, Rhiem K, Gelber R, Loibl S

doi: 10.1016/S1470-2045(25)00546-7

Gastrointestinal Cancer

Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients - A post-hoc analysis of the PETACC 8 trial

Eur J Cancer

Bergen ES, Canton C, Boulin M, Le Malicot K, Bennouna J, Gonzalez D, Mineur L, Bouche O, Lepage C, Taieb J

doi: 10.1016/j.ejca.2025.115643

Gastrointestinal Cancer

FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials

Eur J Cancer

Antoniotti C, Marmorino F, Rossini D, Schmoll HJ, Lonardi S, Tonini G, Borelli B, Cupini S, Stein A, Moretto R, Bergamo F, Ronzoni M, Germani MM, Zaniboni A, Fazio R, De Grandis MC, Ongaro E, Masi G, Cremolini C

doi: 10.1016/j.ejca.2025.115713

Gastrointestinal Cancer

Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysis

Eur J Cancer

Bregni G, Leurquin B, Giasafaki P, Takemura N, Kokudo N, Hasegawa K, Matsuyama Y, Nishioka Y, Aparicio T, Guimbaud R, Malicot KL, Tu D, O'Callaghan C, Lutz MP, Fontana E, Moehler M, Mauer ME, Sclafani F

doi: 10.1016/j.ejca.2025.116092

Head and Neck Cancer

Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial

Exp Hematol Oncol

Fernandez E, Vernet R, Urwyler M, Von Rohr O, Charrier E, Belkouch MC, Saingier V, Courtout F, DeVito C, Ancrenaz V, Dulguerov N, Karenovics W, Grogg J, Renaux J, Gobat K, Müller G, Brezina T, Rordorf T, Joerger M, Michielin O, Villard J, Mach N

doi: 10.1186/s40164-025-00703-x

Gastrointestinal Cancer

Progression-free survival as a surrogate for overall survival in gastro-esophageal cancer trials with immunotherapy: A meta-analysis

Eur J Cancer

Leone AG, Petrelli F, Klempner SJ, Smyth EC, Sundar R, Lordick F, Lorenzen S, Masetti M, Obermannova R, Alsina M, Janjigian YY, Pietrantonio F

doi: 10.1016/j.ejca.2025.116155

Genitourinary CancerFurther Publications

Radiological progression-free survival as a surrogate for overall survival in patients with metastatic hormone-sensitive prostate cancer: A bivariate meta-analysis

Eur J Cancer

Shore N, Morgans AK, Boegemann M, Gallagher E, Paracha N, Serafini P, Pushkarna D, Pourrahmat MM, Kurt M, Abrams KR

doi: 10.1016/j.ejca.2025.115513

Related content

Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis

Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis

Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials

Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients - A post-hoc analysis of the PETACC 8 trial

FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials

Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysis

Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial

Progression-free survival as a surrogate for overall survival in gastro-esophageal cancer trials with immunotherapy: A meta-analysis

Radiological progression-free survival as a surrogate for overall survival in patients with metastatic hormone-sensitive prostate cancer: A bivariate meta-analysis